rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Zachary Roberts

President and CEO

Company insider

Files Form 4 as: President and CEO, Allogene Therapeutics; Chief Medical Officer, Instil Bio.

In numbers

Trades disclosed
27
Buys
0
Sells
4
Bought
$0
Sold
$289K
Companies
2
Companies where not an officer
0
First trade
18 Mar 2021
Last trade
1 Jul 2026
Last filed
6 Jul 2026

Companies traded

Where they are an officer
ALLO Allogene TherapeuticsOfficer · Biotechnology · last 1 Jul 20260 buys · 4 sells
TIL Instil BioOfficer · Biotechnology · last 4 Mar 20220 buys · 0 sells

Activity over time

1 Jan 2025 – 1 Oct 2026
10Jan 25Jun 25Dec 25May 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Jul 2026filed 6 Jul 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—134,530 at $0.00filing
1 Jul 2026filed 6 Jul 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—476,190 at $0.00filing
1 Jul 2026filed 6 Jul 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—134,530 at $0.00filing
1 Jul 2026filed 6 Jul 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—476,190 at $0.00filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$63K35,700 at $1.77filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—718,763 at $0.00filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—203,307 at $0.00filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—718,763 at $0.00filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—203,307 at $0.00filing
2 Feb 2026filed 4 Feb 2026ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$63K35,700 at $1.77filing
21 Jan 2026filed 23 Jan 2026ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$41K26,269 at $1.56filing
21 Jan 2026filed 23 Jan 2026ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$41K26,269 at $1.56filing
3 Feb 2025filed 5 Feb 2025ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$32K18,832 at $1.70filing
24 Jan 2025filed 28 Jan 2025ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—614,844 at $0.00filing
24 Jan 2025filed 28 Jan 2025ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Code A—173,913 at $0.00filing
21 Jan 2025filed 23 Jan 2025ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Sold$48K27,199 at $1.78filing
25 Jan 2024filed 31 Jan 2024ALLO Allogene Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—494,949 at $0.00filing
25 Jan 2024filed 31 Jan 2024ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Code A—140,000 at $0.00filing
22 Jan 2024filed 24 Jan 2024ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Code F$78K24,690 at $3.17filing
22 Mar 2023filed 24 Mar 2023ALLO Allogene TherapeuticsBiotechnologySEC FORM 4 Code A—148,035 at $0.00filing

News

Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026

0 headlines in the last 90 days name Zachary Roberts; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care4

Buys in green, sells in red, by the company’s sector.

Related people

Geoffrey M. ParkerChief Financial Officer · Chief Financial Officer at Allogene Therapeutics, filing Form 4 there in the last year
Earl Martin DouglasSVP, General Counsel · SVP, General Counsel at Allogene Therapeutics, filing Form 4 there in the last year
Elizabeth A. BarrettDirector · Director at Allogene Therapeutics, filing Form 4 there in the last year
Joshua A. KazamDirector · Director at Allogene Therapeutics, filing Form 4 there in the last year
Franz B. HumerDirector · Director at Allogene Therapeutics, filing Form 4 there in the last year